Study of RTMS Analgesic Effect in Chronic Neuropathic Pain,

NCT ID: NCT04936646

Last Updated: 2024-12-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-07-16

Study Completion Date

2025-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the analgesic effectiveness of three modes of repetitive Transcranial Magnetic Stimulation (rTMS) in chronic neuropathic pain:

* Classical rTMS stimulation
* Deeper rTMS stimulation
* Sham rTMS stimulation

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conduct of study:

* Entry into the study: After informed consent, patients will be randomised. The physician responsible for conducting neurostimulation sessions will make the randomization via an interactive web response system (IWRS). Only this physician will have the knowledge of the group allocated to the patient.
* Baseline : Patients, will record on a diary form, a daily Visual Numeric Scale(VNS) of Pain Intensity for 1 week.
* Treatment sessions: after the baseline, sessions of neurostimulation will begin for seven weeks.
* After the end of neurostimulation sessions, patients will be followed for 2 weeks.
* Throughout their participation in the study, patients will plot on a diary form their daily VNS.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Neuropathic Pain

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

rTMS Chronic neuropathic pain Repetitive Transcranial Magnetic Stimulation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Classic rTMS Stimulation using the B65 Coil

Group Type EXPERIMENTAL

RepetitiveTranscranial Magnetic Stimulation (rTMS)

Intervention Type DEVICE

The rTMS protocol consist of one session per day for five days during the first week, then three sessions the second week and then one session the third week, followed by two monthly sessions.

Deeper rTMS Stimulation using the B70 Coil

Group Type EXPERIMENTAL

RepetitiveTranscranial Magnetic Stimulation (rTMS)

Intervention Type DEVICE

The rTMS protocol consist of one session per day for five days during the first week, then three sessions the second week and then one session the third week, followed by two monthly sessions.

control group with a sham stimulation using a sham coil

Group Type SHAM_COMPARATOR

RepetitiveTranscranial Magnetic Stimulation (rTMS)

Intervention Type DEVICE

The rTMS protocol consist of one session per day for five days during the first week, then three sessions the second week and then one session the third week, followed by two monthly sessions.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RepetitiveTranscranial Magnetic Stimulation (rTMS)

The rTMS protocol consist of one session per day for five days during the first week, then three sessions the second week and then one session the third week, followed by two monthly sessions.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient's written consent
* Affiliated with social security system
* Male or female, suffering for more than a year from unilateral refractory neuropathic pain: hemi-body, upper limb, lower limb and facial chronic pain.
* Patient whose analgesic treatment, is stable for at least 1 month.
* Patient not responding to conventional treatments
* Prescreening EVN \>3

Exclusion Criteria

* History of drug addiction, epilepsy, cranial trauma
* History of psychiatric disorder
* Patients previously treated with rTMS
* Patient with intracranial ferromagnetic material or implanted stimulator
* New treatment for less than one month
* Pregnant or Breastfeeding woman
* Patient who does not understand the study protocol
* Persons who are protected under the act.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Grenoble

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hasan HODAJ, MD

Role: PRINCIPAL_INVESTIGATOR

CHUGA

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre de la douleur, CHU Grenoble Alpes

Grenoble, Isère, France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Hasan HODAJ, MD

Role: CONTACT

Phone: 04-76-76-52-13

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

HODAj Hasan, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

38RC20192

Identifier Type: -

Identifier Source: org_study_id